Nurix Therapeutics, Inc. (NRIX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $27.26
- As of
Kresmion compiles this page from NRIX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Nurix Therapeutics, Inc. (NRIX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-13.
See the full NRIX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NRIX on one page. Preview it with sample data, then open it live with a free account.
Preview the NRIX dossierActive events for NRIX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 871.7%, EPS $4.73 vs $-0.6129 estimate
- high13F: funds reduced
3 tracked funds reduced NRIX this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 79% of NRIX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +2563% to NRIX (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 84% of NRIX (2026Q2)
FREE, NO ACCOUNT
Every event on NRIX, as it fires
You are seeing 5 of 16 events recorded on NRIX since 2026-06-10.
The five above landed across 2 days. The other 11 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NRIX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 67080M103 · 2026Q2 | $35.8M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 67080M103 · 2026Q2 | $4.5M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 67080M103 · 2026Q2 | $1.8M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 67080M103 · 2026Q2 | $507K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NRIX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NRIX mentioned in Kresmion daily briefs
NRIX against its peers
NRIX's operating margin of -340.2% ranks in the 47th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | NRIX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 84.0M USD | 70.8M USD | 58 | 17 |
| Gross margin | n/a | 58.3% | n/a | 7 |
| Operating margin | -340.2% | -274.6% | 47 | 15 |
| Net margin | -314.9% | -162.9% | 47 | 15 |
| Return on equity | -49.1% | -29.6% | 34 | 24 |
Peers (24): BEAM, DNLI, TLX, DYN, VKTX, VRDN, ATAI.D, IDYA, ELVN, GRTX.D, CELC, MBX, RXRX, ZLAB, ACAD, ADMA, XENE, NAMS, IRON, TNGX, BHVN, CLDX, RCUS, AUPH. Left out: PBLS (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NRIX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NRIX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NRIX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.